Zymeworks Licenses Trispecific T Cell Engager Targeting DLL3 to Roche
Zymeworks will run the Phase 1a monotherapy study in collaboration with Roche, which funds the trial and then takes over global development.

Key Points
- Zymeworks has entered a global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3.
- Zymeworks is eligible for a $55 million upfront payment, a $40 million payment upon Phase 1b initiation, up to $718 million in milestones, and tiered royalties.
- Zymeworks will conduct the Phase 1a monotherapy trial, funded by Roche, following FDA investigational new drug clearance.
Zymeworks Inc., a biotechnology company developing multifunctional biotherapeutics, announced a global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. The agreement covers research, development, and commercialization of ZW209.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
Zymeworks is eligible to receive a $55 million upfront payment, a $40 million payment upon initiation of the Phase 1b trial, additional development, commercial, and sales-based milestones of up to $718 million, and tiered high-single-digit to mid-teen royalties on net sales of any approved medicines resulting from the collaboration. The transaction remains subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
Zymeworks will conduct the Phase 1a monotherapy trial of ZW209 in collaboration with Roche. Roche will fund the trial and will be responsible for subsequent global development and commercialization, holding the exclusive right to develop and commercialize ZW209 globally.
“This collaboration allows us to continue advancing ZW209 through its initial clinical development while leveraging Roche’s complementary capabilities to accelerate and expand its development across indications and treatment settings. The agreement also reflects our broader strategy of generating innovative programs through our R&D engine and partnering selected assets in ways that share development risk while preserving meaningful participation in their future success,” said Adam Schayowitz, Ph.D., MBA, Executive Vice President and Head of R&D at Zymeworks.
“ZW209 represents an innovative approach that complements our ongoing efforts to develop new treatment options for people living with lung cancer,” said Boris L. Zaïtra, Head of Corporate Business Development at Roche. “We look forward to collaborating with Zymeworks to fully explore its therapeutic potential.”
ZW209
ZW209 is a trispecific T cell engager developed to target DLL3-expressing tumor cells while engaging T cells through CD3 and CD28. Configured using Zymeworks’ TriTCE Co-Stim and Azymetric and EFECT platforms, ZW209 is designed to enhance anti-tumor T cell responses through CD28 co-stimulation. The company describes obligate cis-T cell binding and conditional CD28 engagement as mechanisms to prevent unintended T cell activation while enabling tumor-targeted cytotoxicity.
Preclinically, Zymeworks reported that ZW209 demonstrated differentiated long-term cytotoxicity in vitro, with enhanced T cell proliferation and survival, suggesting potential to increase durability of responses in DLL3-expressing cancers.
Following FDA investigational new drug clearance, a Phase 1, open-label, multicenter, global study of ZW209 has been initiated to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The study will enroll adults with select advanced solid tumors, including small cell lung cancer and other DLL3-expressing neuroendocrine tumors. Additional global regulatory applications are planned to support opening clinical study sites outside the U.S.
Broader Portfolio
The collaboration is part of Zymeworks’ strategy to advance differentiated candidates internally while selectively partnering programs where complementary capabilities can accelerate development. Beyond ZW209, Zymeworks has research programs of multispecific T cell engagers against targets in solid tumors, hematological tumors, and autoimmune and inflammatory diseases.
Zymeworks will host a conference call with investment analysts at 8:30 am Eastern Time on October 27, 2026. Dial-in details and webcast access are available at Zymeworks’ investor relations site.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
California Agency Awards $9 Million to Enloe Health for Northern California Regenerative Medicine Access Center
UConn Health Launches CAR-T Cell Therapy Program for Blood Cancers
AbelZeta Receives FDA RMAT and Fast Track Designations for Anti-CD20/CD19 Bispecific CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma
Octane Biotech and Currus Biologics Automate CAR T-Cell Therapy Manufacturing
Cellares and GenomeFrontier Therapeutics Partnering on Automated Virus-Free CAR-T Program for Phase 1
Vyriad Begins Mayo Clinic CAR-T Phase 1 for Multiple Myeloma
FDA Clears Colorado University Anschutz’ CAR T-Cell Trial for Colorectal Cancer
University Hospital Tuebingen’s New Trial Tests CD19 CAR T-Cell Therapy for Autoimmune Diseases







